Led · Series A · May 2026

Founded in September 2025, Sonomind develops non-invasive ultrasound-based treatments aimed at neuropsychiatric conditions, notably treatment-resistant depression. The company plans to enter clinical studies to generate the evidence required for regulatory approvals and aims for CE marking and FDA clearance by 2029. Financially, Sonomind completed a €3 million seed round in 2025 and followed with a €20 million Series A in 2025 that includes €2 million of debt. Leadership includes cofounder Jérémy Bercoff, a physicist with fifteen years’ experience at SuperSonic Imagine. Sonomind is also exploring addressing the Asian market as part of its international expansion plans.

Led · Seed · Mar 2026

Ilion Water Technologies is building a next-generation water desalination and purification platform that replaces energy-intensive, high-pressure systems with a patented, highly charged membrane that operates on just a few volts of electricity. The approach enables pressure-free, chemical-optimised filtration, promising lower costs and energy usage compared with traditional reverse-osmosis solutions. Fresh capital will fund the expansion of its team of scientists and engineers and support the company’s move from ENS-PSL research laboratories into industrial environments. Near-term plans include completing technological scale-up and launching field trials with industrial partners to validate robustness in real-world conditions. The company has secured €3.8 million to date, including €1.3 million in non-dilutive grants, providing runway for these milestones. No commercial revenue or user metrics were disclosed in the announcement.

Participated · Series A · Sep 2025

RDS is a medtech company focused on remote patient monitoring. Its flagship product, MultiSense, is a patented telemonitoring system that the company develops, manufactures and markets. The company collaborates with international research initiatives such as DARE and 5G-OR and has been incubated at SEMIA/Quest for Health while being accelerated by PariSanté Campus. Emphasizing an eco-conscious approach, RDS aims to set new standards for telemonitoring across Europe. With its latest funding, the firm plans to expand commercialization in France, Germany and the broader European market and to conduct additional clinical trials to support reimbursement applications. The team is simultaneously preparing for FDA registration with the goal of entering the U.S. market in 2028. Elie Lobel leads the company as CEO, and no revenue or user metrics have been disclosed.